# Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study

> **NCT07440537** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 105 (estimated)

## Conditions studied

- Cutaneous Lupus Erythematosus (CLE)

## Interventions

- **DRUG:** ICP-488 Tablets
- **DRUG:** ICP-488 Tablets
- **OTHER:** ICP-488 Placebo

## Key facts

- **NCT ID:** NCT07440537
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2027-03
- **Final completion:** 2027-12
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07440537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07440537, "Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT07440537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*